How to Get Vyvanse in South Carolina

Who Can Prescribe Vyvanse in South Carolina

Any prescriber holding an active South Carolina medical license, a valid DEA registration, and a state-controlled-substance registration may write a Vyvanse prescription. That includes MDs, DOs, nurse practitioners with full prescriptive authority, and physician assistants operating under a supervising physician's scope-of-practice agreement.

South Carolina grants NPs prescriptive authority for Schedule II substances after they complete a minimum of 45 contact hours of pharmacology education and maintain a written practice agreement, though full-practice-authority legislation has been proposed but not yet enacted as of early 2026. PAs in South Carolina prescribe under a supervisory agreement that must be filed with the SC Board of Medical Examiners; their DEA registration piggybacks off the supervising physician's practice site. Both NPs and PAs can prescribe lisdexamfetamine for ADHD or binge eating disorder as long as controlled-substance prescribing is explicitly included in their scope.

A psychiatrist or psychiatric NP is not strictly required. Primary care physicians manage the majority of adult ADHD prescriptions nationally. According to data published in JAMA Network Open, approximately 73.2% of adult stimulant prescriptions are written by non-psychiatrists, including family medicine and internal medicine providers. If your current provider in South Carolina is unwilling to prescribe a stimulant, a referral to a psychiatrist or a telehealth ADHD platform may be the most direct path.

Telehealth Prescribing Rules for Vyvanse in South Carolina

South Carolina permits Schedule II controlled substances to be prescribed via telehealth when the prescriber establishes a bona fide provider-patient relationship. This typically requires a synchronous audio-video evaluation, not audio-only.

The South Carolina Board of Medical Examiners follows the state Telemedicine Act (S.C. Code § 40-47-37), which requires that the telehealth prescriber either holds a full SC medical license or practices under the Interstate Medical Licensure Compact. South Carolina is a member of the IMLC, so physicians licensed through the Compact can see SC patients remotely without a separate state license.

For ADHD evaluations conducted via telehealth, most platforms use validated screening instruments such as the Adult ADHD Self-Report Scale (ASRS-v1.1) alongside a structured clinical interview. The DSM-5 diagnostic criteria require documentation of symptom onset before age 12 and evidence of functional impairment across two or more settings. A prescriber who initiates Vyvanse via telehealth may require an in-person follow-up or an established local prescriber for ongoing refills, depending on the platform's clinical protocols and the DEA's evolving telehealth prescribing framework.

Refill timing matters. Because Vyvanse is Schedule II, South Carolina law does not permit refills on the original prescription. A new prescription must be issued each time, though electronic prescribing for controlled substances (EPCS) is legal and increasingly standard in the state.

What Labs and Evaluations Are Needed Before Starting Vyvanse

Lisdexamfetamine does not require pre-treatment laboratory monitoring by FDA labeling. The Vyvanse prescribing information recommends assessing cardiovascular status before initiation, particularly in patients with known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease.

Most South Carolina prescribers follow this clinical checklist before writing the first prescription:

• Vital signs: Baseline blood pressure and resting heart rate. Lisdexamfetamine raises systolic blood pressure by an average of 1 to 4 mmHg and heart rate by 2 to 6 bpm at therapeutic doses, per FDA labeling data.
• Cardiac history screen: Family history of sudden death, personal history of syncope or chest pain. An EKG is not universally required but is reasonable in patients with suggestive histories.
• Substance use screening: The American Academy of Family Physicians recommends assessing for current or past substance use disorders before prescribing any stimulant, though a positive history is not an automatic contraindication.
• Psychiatric history: Screening for bipolar disorder, psychotic features, and active suicidal ideation, since stimulants can exacerbate manic episodes and are relatively contraindicated in primary psychotic disorders.
• Growth parameters (pediatric): Height and weight should be tracked longitudinally. The Wigal et al. study (N=314) found that lisdexamfetamine-treated children experienced a mean weight decrease of 3 to 5 lb over the first 4 weeks, with growth velocity normalizing for most children by 12 to 15 months of treatment (Wigal et al., J Atten Disord, 2017).

No routine blood work (CBC, hepatic panel, thyroid studies) is required by the label, though some prescribers obtain baseline thyroid function to rule out thyroid disease as a contributing cause of attention difficulties.

South Carolina Medicaid and Vyvanse Coverage

Vyvanse is not covered by South Carolina Medicaid under the state's preferred drug list. This is a significant barrier for the roughly 1.1 million South Carolinians enrolled in Medicaid or the Children's Health Insurance Program.

The South Carolina Department of Health and Human Services manages its PDL through Magellan Medicaid Administration. For ADHD, SC Medicaid's preferred formulary favors generic immediate-release and extended-release mixed amphetamine salts (Adderall, Adderall XR generics) and methylphenidate formulations. Generic lisdexamfetamine became available in August 2023 when the FDA approved several ANDA filings, which has lowered cash prices, but the generic is not yet on SC Medicaid's PDL either.

For patients who have documented failure of or intolerance to at least two preferred agents, prescribers can submit a prior authorization request. The PA process typically requires:

1. Documentation of trials with at least two formulary-preferred stimulants (name, dose, duration, and reason for discontinuation).
2. A letter of medical necessity from the prescribing provider.
3. The patient's current diagnosis codes (F90.0, F90.1, F90.2 for ADHD; F50.81 for binge eating disorder).
4. Processing time of 24 to 72 hours for standard requests; 24 hours for urgent requests.

For patients with commercial insurance, most major carriers in South Carolina (BlueCross BlueShield of South Carolina, Absolute Total Care, Molina Healthcare) cover brand Vyvanse with a prior authorization or step therapy requirement. Takeda's Vyvanse savings card can reduce copays to as low as $30 per month for commercially insured patients, though it cannot be applied to any government-funded plan.

Pharmacy Access and 503A Compounding in South Carolina

South Carolina has approximately 1,400 licensed retail pharmacies across its 46 counties, with major chains (CVS, Walgreens, Walmart) carrying standard Vyvanse capsule inventory. Generic lisdexamfetamine availability has been stable at most large-chain pharmacies since late 2024 after initial supply disruptions in the 2022 to 2023 period.

For patients seeking compounded lisdexamfetamine, South Carolina does license 503A compounding pharmacies. These pharmacies can compound lisdexamfetamine for an individual patient when a prescriber writes a patient-specific prescription, typically for dose adjustments that commercial capsules do not offer (for example, a 15 mg or 35 mg dose). A 503A pharmacy must comply with USP 795 and 800 standards and cannot produce bulk quantities without individual prescriptions.

A few points about filling a Vyvanse prescription at SC pharmacies:

• Transfer rules: Schedule II prescriptions cannot be transferred between pharmacies under federal law. If your prescription is sent electronically to the wrong pharmacy, the prescriber must void it and issue a new one.
• Partial fills: Federal law now permits partial dispensing of Schedule II prescriptions at the patient's or prescriber's request, with the remaining balance fillable within 30 days of the original date.
• Mail-order: Some SC patients use mail-order pharmacies such as Express Scripts or CVS Caremark for 90-day supplies. The prescription must still originate from a provider licensed in South Carolina or in the patient's state of residence, and the mail-order pharmacy must hold an SC non-resident pharmacy license.

Dose Initiation and Titration Protocol

The standard starting dose for adults with ADHD is 30 mg once daily in the morning, per FDA labeling. Clinicians titrate in 10 mg or 20 mg increments at weekly intervals based on efficacy and tolerability. The maximum approved dose is 70 mg/day for ADHD.

For binge eating disorder, the starting dose is also 30 mg/day, titrated to a target of 50 to 70 mg/day. The McElroy et al. key trials (two phase 3 studies, combined N=724) demonstrated a 3.87 reduction in weekly binge days at the 70 mg dose compared to 0.51 for placebo over 12 weeks. This effect size was consistent across BMI subgroups.

For children ages 6 to 12, initial dosing is 30 mg/day. The Wigal et al. study in the Journal of Attention Disorders (N=314) showed that children treated with lisdexamfetamine 30 to 70 mg/day had a mean improvement of 18.6 points on the ADHD-RS-IV total score compared to 5.2 points for placebo at endpoint (Wigal et al., 2017). The duration of behavioral effect is approximately 13 hours, which covers a full school day and after-school period.

Lisdexamfetamine is a prodrug. It requires enzymatic cleavage of the lysine moiety in red blood cells to release active d-amphetamine. This conversion mechanism produces a smoother pharmacokinetic curve than immediate-release amphetamine and reduces abuse liability. A 2012 study published in the Journal of Clinical Psychopharmacology found that intranasal and intravenous lisdexamfetamine produced significantly lower "drug liking" scores compared to equivalent doses of immediate-release d-amphetamine.

Transferring a Vyvanse Prescription to South Carolina

If you are relocating to South Carolina with an existing Vyvanse prescription from another state, the prescription itself cannot transfer. Schedule II prescriptions do not transfer between pharmacies, and an out-of-state prescriber cannot write a new SC prescription without proper licensure.

Your practical options are:

1. Request your medical records from your current prescriber before moving. Include the most recent clinical note, your ADHD or BED diagnosis, current dose, and any prior authorization documentation.
2. Establish care with an SC-licensed provider who can review your records and write a new prescription. Many telehealth platforms can see you within 3 to 7 days.
3. Emergency supply: South Carolina pharmacists may dispense a 72-hour emergency supply of a Schedule II medication under SC Code § 40-43-86 when the prescriber is unavailable, to prevent interruption of critical therapy. This is pharmacist-discretionary and not guaranteed.

Plan ahead. A lapse in stimulant therapy is not medically dangerous in the way that abrupt discontinuation of benzodiazepines or opioids can be, but rebound ADHD symptoms, fatigue, and increased appetite are common within 24 to 48 hours of the last dose.

Cost Without Insurance in South Carolina

Brand Vyvanse 30-day supply (any dose) carries a cash price of roughly $380 to $450 at most South Carolina retail pharmacies. Generic lisdexamfetamine runs $150 to $250 for a 30-day supply without insurance, though GoodRx and similar discount platforms often bring the generic below $100 at Walmart and Costco locations.

Takeda's patient assistance program (Takeda HELP at Hand) covers Vyvanse at no cost for uninsured patients with household incomes below 250% of the federal poverty level ($37,650 for a single individual in 2026). The application requires documentation of income and a signed prescription from an active provider.

For commercially insured patients facing high copays, the Vyvanse savings card offered by Takeda can reduce out-of-pocket costs to $30 per fill, with a maximum annual benefit of $3,600. This cannot be combined with Medicare, Medicaid, TRICARE, or other federal programs.